Ozempic Maker Novo Gets Calls From ‘Scared’ Food CEOs (1)

Makers of everything from snack food to knee implants are facing a potential threat from Novo Nordisk A/S’s powerful appetite-suppressing treatments. So they’re calling the drugmaker for advice.

“A couple of CEOs from, say, food companies have been calling me,” Novo Chief Executive Officer Lars Fruergaard Jorgensen said during a wide-ranging discussion in New York. He declined to name names, saying questions had centered on how the drugs work and how fast they would roll out. “They are scared about it.”

The impact of the drugs, including Ozempic and Wegovy, could vary across industries, Jorgensen said. He pointed to ...